Floatz logo

Rucacuzumab

Ischemic Stroke

Peking Union Medical College HospitalUNKNOWNPhase 4 / ApprovedActive
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
89/ 100

Competitive context

197 Active assets in the Ischemic Stroke cohort.

Asset / SponsorPhaseRating
Ticagrelor
Sichuan Provincial People's Hospital
Phase 4BBB
Cilostazol
Stanford University
Phase 4BBB
Compound Edaravone
Nanfang Hospital, Southern Medical University
Phase 4BBB
3-N-BUTYLPHTHALIDE
Nanfang Hospital, Southern Medical University
Phase 4BBB
Argatroban
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 4BBB

View all 50 →

Same molecule, other indications

Rucacuzumab is also rated in:

cerebral atherosclerosisActive
BB
Indicative · Phase 4
65 / 100
View asset →
atherosclerosisActive
BB
Indicative · Phase 4
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →